Drug intelligence / Profile preview

ivonescimab + sacituzumab govitecan

Development stage: Unknown
Lead developer: Akeso
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Ivonescimab + sacituzumab govitecan is an investigational combination therapy being evaluated for the treatment of triple-negative breast cancer (TNBC), specifically in patients with brain metastases. Ivonescimab (AK112) is a first-in-class bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), designed to combine immunotherapy with anti-angiogenesis. Sacituzumab govitecan is a TROP2-directed antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody conjugated to the topoisomerase I inhibitor SN-38. This combination aims to leverage the synergistic effects of immune checkpoint inhibition, anti-angiogenesis, and cytotoxic chemotherapy delivered via a targeted ADC to overcome resistance in advanced malignancies.

Brand names: Trodelvy
Other names: ivonescimab + TROP2 ADCAK112 + sacituzumab govitecanAK112 + IMMU-132ivoximab + TROP2 ADC

Targets

VEGFA (Vascular endothelial growth factor A)TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)TACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on ivonescimab + sacituzumab govitecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ivonescimab + sacituzumab govitecan.

Explore the full profile